V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330012612 | 330003189 | null | 103.4 | Radical (R) | 2014-05-15 | 2014-11-09 | NB HRNBL-1 COJEC Ind COURSE B | N | null | 330001612 | NOT MATCHED |
| 330012613 | 330003233 | 1.72 | 60.8 | Curative (C) | 2016-10-19 | 2016-11-15 | Cisplatin 100 + RT(H&N) 1 day | 02 | Y | 330001982 | CISPLATIN + RT |
| 330012614 | 330007725 | 0 | 11.4 | Curative (C) | 2017-09-08 | 2017-11-10 | NB HRNBL-1 COJEC Ind COURSE C | N | null | 330002044 | NOT MATCHED |
| 330012615 | 330007756 | 0 | 6.8 | Palliative (P) | 2014-04-01 | 2014-04-01 | NB HRNBL-1 TVD | 02 | Y | 330002460 | NOT MATCHED |
| 330012616 | 330003314 | 1.78 | 83.1 | Curative (C) | 2015-09-16 | 2015-10-25 | CISPLATIN + RT | N | Y | 330002530 | CISPLATIN + RT |
| 330012617 | 330010235 | 1.7 | 46 | Curative (C) | 2016-04-29 | 2016-04-29 | Cisplatin 100 + RT(H&N) 1 day | 2 | Y | 330002705 | CISPLATIN + RT |
| 330012618 | 330003384 | 1.78 | 78.7 | Curative (C) | 2016-11-04 | 2016-11-18 | CISPLATIN + RT | N | null | 330002981 | CISPLATIN + RT |
| 330012619 | 330003445 | 1.71 | 0 | Curative (C) | 2017-01-02 | 2017-01-09 | Cisplatin 100 + RT(H&N) 1 day | 02 | N | 330003339 | CISPLATIN + RT |
| 330012620 | 330003449 | 1.6 | 51.8 | 2 | 2015-07-17 | 2015-08-11 | Cisplatin 100 + RT(H&N) 1 day | 02 | Y | 330003346 | CISPLATIN + RT |
| 330012621 | 330010266 | 0 | 15.2 | Palliative (P) | 2015-02-21 | 2015-02-24 | NB HRNBL-1 TVD | N | null | 330003386 | NOT MATCHED |
| 330012622 | 330003464 | 1.62 | null | Adjuvant (A) | 2016-08-02 | 2016-08-02 | Cisplatin 100 + RT(H&N) 1 day | N | null | 330003394 | CISPLATIN + RT |
| 330012623 | 330003468 | null | 11.2 | Curative (C) | 2018-02-19 | 2018-03-03 | CNS LGG 2004 03 cons vinc +cyclo | 02 | N | 330003402 | NOT MATCHED |
| 330012624 | 330007866 | 0 | 18.2 | Curative (C) | 2015-06-28 | 2015-08-23 | AML Interim Guidelines FLAG | Y | Y | 330003518 | NOT MATCHED |
| 330012625 | 330003495 | 0 | 32.4 | Neo-adjuvant (N) | 2013-09-10 | 2014-04-01 | NB 13 cis-RA (Isotretinoin) | null | null | 330003536 | NOT MATCHED |
| 330012626 | 330003500 | 0 | 86.05 | Palliative (P) | null | 2017-08-30 | NB HRNBL-1 Isotretinoin | 02 | N | 330003568 | NOT MATCHED |
| 330012627 | 330003519 | 1.67 | 13.1 | Palliative (P) | 2016-03-01 | 2016-03-10 | NB HRNBL-1 COJEC Ind COURSE C | 02 | null | 330003643 | NOT MATCHED |
| 330012628 | 330003534 | 1.6 | 13.8 | Palliative (P) | 2014-07-18 | 2014-12-26 | NB HRNBL-1 Isotretinoin | N | N | 330003735 | NOT MATCHED |
| 330012629 | 330003536 | 1.83 | 86.9 | Radical (R) | 2017-07-02 | 2017-08-05 | Cisplatin + Radiotherapy | 02 | N | 330003743 | CISPLATIN + RT |
| 330012631 | 330003546 | 1.75 | 19 | Curative (C) | 2017-12-26 | 2017-12-30 | CNS LGG 2004 03 cons vinc + carbo | 01 | N | 330004796 | NOT MATCHED |
| 330012632 | 330003548 | 1.6 | 77 | Curative (C) | null | 2015-11-02 | LCHIV Cont A | N | null | 330004842 | NOT MATCHED |
| 330012633 | 330003552 | null | 68.1 | Curative (C) | 2017-09-18 | 2017-09-18 | NB HRNBL-1 Isotretinoin | 02 | N | 330004963 | NOT MATCHED |
| 330012634 | 330003553 | null | 14.2 | Neo-adjuvant (N) | 2017-04-23 | 2017-04-23 | ALL Interfant 06 Protocol 1B | N | null | 330004971 | NOT MATCHED |
| 330012635 | 330003565 | null | 11 | Palliative (P) | 2014-09-01 | 2014-09-06 | NB HRNBL-1 COJEC Ind COURSE C | N | null | 330005102 | NOT MATCHED |
| 330012636 | 330003591 | 0 | 47.5 | Adjuvant (A) | 2018-04-24 | 2018-05-16 | NB HRNBL-1 COJEC Ind COURSE A | N | N | 330005262 | NOT MATCHED |
| 330012637 | 330003603 | 1.61 | 87 | null | 2014-11-18 | 2014-11-18 | Mifamurtide weeks 13-36 | 02 | N | 330005305 | MIFAMURTIDE |
| 330012638 | 330003611 | null | 52.35 | Curative (C) | null | 2015-11-30 | Mifamurtide weeks 1-12 | Y | null | 330005334 | MIFAMURTIDE |
| 330012639 | 330003614 | null | 51 | Adjuvant (A) | 2016-01-12 | 2016-01-16 | Trial Unspecified | null | null | 330005358 | TRIAL |
| 330012640 | 330003617 | 1.77 | 53.4 | Neo-adjuvant (N) | 2016-05-04 | 2016-05-31 | Trial Unspecified | null | null | 330005388 | TRIAL |
| 330012641 | 330003627 | null | 75.4 | Curative (C) | 2016-04-29 | 2016-07-10 | DOXORUBICIN | null | null | 330005461 | DOXORUBICIN |
| 330012642 | 330003632 | 0 | null | null | 2017-06-02 | 2018-04-20 | METHOTREXATE | N | N | 330005520 | METHOTREXATE |
| 330012643 | 330003646 | 1.04 | 54.4 | Curative (C) | null | 2016-08-13 | METHOTREXATE | Y | null | 330005587 | METHOTREXATE |
| 330012644 | 330003650 | 1.6 | 19.5 | Curative (C) | 2017-05-15 | 2018-06-24 | DOXORUBICIN | Y | N | 330005616 | DOXORUBICIN |
| 330012645 | 330003663 | null | 45 | Palliative (P) | null | 2018-03-02 | DOXORUBICIN | null | null | 330005682 | DOXORUBICIN |
| 330012646 | 330007984 | 1.72 | 38.6 | null | 2017-04-19 | 2017-12-21 | MIFAMURTIDE | 02 | N | 330005732 | MIFAMURTIDE |
| 330012647 | 330003687 | 1.65 | 73.7 | Curative (C) | 2016-09-07 | 2017-10-18 | METHOTREXATE | 01 | N | 330005735 | METHOTREXATE |
| 330012648 | 330003696 | 1.79 | 14.55 | Curative (C) | null | 2016-07-18 | DOXORUBICIN | null | null | 330005861 | DOXORUBICIN |
| 330012649 | 330007992 | 1.74 | 97.1 | Palliative (P) | 2015-10-30 | 2016-04-25 | Mifamurtide weeks 1-12 | null | null | 330005868 | MIFAMURTIDE |
| 330012650 | 330003705 | null | 63.4 | Curative (C) | 2017-05-25 | 2017-05-25 | Mifamurtide weeks 1-12 | 02 | N | 330005896 | MIFAMURTIDE |
| 330012651 | 330007998 | 1.61 | 81.2 | Adjuvant (A) | 2019-06-13 | 2019-06-13 | MIFAMURTIDE | null | N | 330005922 | MIFAMURTIDE |
| 330012653 | 330003725 | 1.76 | null | Neo-adjuvant (N) | null | 2015-07-07 | DOXORUBICIN | N | null | 330006003 | DOXORUBICIN |
| 330012654 | 330003727 | 1.77 | 96 | Curative (C) | 2015-04-28 | 2015-09-23 | Cisplatin | null | null | 330006006 | CISPLATIN |
| 330012655 | 330003741 | null | 65.8 | Curative (C) | 2013-04-30 | 2013-11-23 | Trial Unspecified | 02 | N | 330006058 | TRIAL |
| 330012656 | 330003751 | 1.63 | null | Curative (C) | 2014-03-17 | 2014-09-19 | DOXORUBICIN | null | null | 330006926 | DOXORUBICIN |
| 330012657 | 330003755 | null | 60.6 | Curative (C) | 2013-06-06 | 2013-11-21 | MIFAMURTIDE | N | null | 330007195 | MIFAMURTIDE |
| 330012658 | 330008030 | 1.91 | null | Neo-adjuvant (N) | 2016-12-02 | 2017-04-11 | EW EuroEwing 2012 Arm B IE | N | N | 330007214 | TRIAL |
| 330012659 | 330003764 | 0 | 109.4 | Curative (C) | null | 2014-05-11 | OST Euramos 1 Closed Trial - A | N | null | 330007247 | DOXORUBICIN |
| 330012660 | 330008035 | 1.82 | 49.8 | null | 2016-10-16 | 2016-10-28 | MIFAMURTIDE | N | Y | 330007251 | MIFAMURTIDE |
| 330012661 | 330010362 | 1.76 | 35.3 | Adjuvant (A) | 2014-04-23 | 2014-04-23 | Methotrexate Intermed dose (1g/m2) | 01 | N | 330007345 | METHOTREXATE |
| 330012662 | 330008048 | 1.82 | 75.4 | Curative (C) | 2016-06-16 | 2016-06-16 | MIFAMURTIDE | N | N | 330007358 | MIFAMURTIDE |
| 330012663 | 330008049 | 1.68 | 71.2 | Neo-adjuvant (N) | 2014-06-10 | 2014-07-28 | METHOTREXATE | N | N | 330007359 | METHOTREXATE |